S7326

SB 657510

≥98% (HPLC)

• 别名: 2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide, SB-657510
• 经验公式（希尔记法）: C₁₉H₂₂BrClN₂O₅S
• CAS号: 474960-44-6
• 分子量: 505.81
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329824581
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to off-white
• 溶解度: DMSO: ≥30 mg/mL
• 起源: GlaxoSmithKline
• 儲存溫度: room temp
• SMILES 字串: COc1cc(Br)c(cc1OC)S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2
• InChI: 1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1
• InChI 密鑰: KQCZCINJGIRLCD-CYBMUJFWSA-N

说明

應用

SB 657510 may be used to study the urotensin II receptor-mediated signaling.

生化／生理作用

SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.¹

SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.

特點和優勢

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全信息

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H315,H319,H335
• 防範說明: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• 危險分類: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable